What's new? Log in Free sign up

PDL Biopharma (PDLI) 8-KPDL BioPharma Provides Fourth Quarter 2012 Royalty Revenue Guidance of $86 Million

Filed: 6 Dec 12, 12:00am

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

PDLI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 99.2

Royalty Revenue by Product ($ in 000's) *

Avastin	Q1		Q2		Q3		Q4		Total
2012	23,215		41,670		25,955		30,041		120,882
2011	22,283		41,967		23,870		22,886		111,006
2010	16,870		44,765		29,989		24,922		116,547
2009	13,605		35,161		21,060		15,141		84,966
2008	9,957		30,480		19,574		12,394		72,405
2007	8,990		21,842		17,478		9,549		57,859
2006	10,438		15,572		15,405		12,536		53,952

Herceptin	Q1		Q2		Q3		Q4		Total
2012	25,702		44,628		30,433		28,307		129,070
2011	25,089		42,209		31,933		21,812		121,042
2010	23,402		38,555		27,952		25,441		115,350
2009	16,003		32,331		26,830		18,615		93,779
2008	14,092		34,383		28,122		20,282		96,880
2007	19,035		28,188		22,582		14,802		84,608
2006	15,142		19,716		21,557		20,354		76,769

Lucentis	Q1		Q2		Q3		Q4		Total
2012	10,791		27,938		12,552		11,097		62,377
2011	8,878		24,313		12,157		10,750		56,099
2010	7,220		19,091		10,841		8,047		45,198
2009	4,621		12,863		8,123		6,152		31,759
2008	3,636		11,060		7,631		4,549		26,876
2007	2,931		6,543		6,579		3,517		19,570
2006	-		-		289		3,335		3,624

Xolair	Q1		Q2		Q3		Q4		Total
2012	5,447		8,609		6,504		6,145		26,705
2011	4,590		7,621		5,916		5,823		23,949
2010	3,723		6,386		4,980		4,652		19,741
2009	2,665		5,082		4,085		3,722		15,553
2008	1,488		4,866		3,569		2,927		12,850
2007	1,684		3,942		3,332		2,184		11,142
2006	2,263		2,969		3,041		2,495		10,768

Perjeta	Q1		Q2		Q3		Q4		Total
2012	-		-		58		250		308
2011	-		-		-		-		-
2010	-		-		-		-		-
2009	-		-		-		-		-
2008	-		-		-		-		-
2007	-		-		-		-		-
2006	-		-		-		-		-

Tysabri	Q1		Q2		Q3		Q4		Total
2012	11,233		12,202		11,749		12,255		47,439
2011	9,891		10,796		11,588		11,450		43,725
2010	8,791		8,788		8,735		9,440		35,754
2009	6,656		7,050		7,642		8,564		29,912
2008	3,883		5,042		5,949		6,992		21,866
2007	839		1,611		2,084		2,836		7,370
2006	-		-		-		237		237

Actemra	Q1		Q2		Q3		Q4		Total
2012	1,705		2,074		2,145		2,462		8,385
2011	913		1,136		1,401		1,460		4,910
2010	1,587		237		315		688		2,827
2009	585		537		909		1,197		3,228
2008	44		-		146		369		559
2007	32		-		-		17		49
2006	-		-		-		-		-

* As reported to PDL by its licensees

Totals may not sum due to rounding

Reported Net Sales Revenue by Product ($ in 000's) *

Avastin	Q1		Q2		Q3		Q4		Total
2012	1,502,757		1,573,727		1,551,327		1,662,977		6,290,788
2011	1,597,461		1,582,705		1,581,095		1,469,994		6,231,255
2010	1,506,788		1,596,892		1,594,707		1,646,218		6,344,605
2009	1,345,487		1,295,536		1,439,730		1,514,053		5,594,806
2008	980,715		1,084,930		1,180,427		1,239,382		4,485,454
2007	678,068		746,587		797,013		875,084		3,096,752
2006	439,318		516,052		570,551		592,897		2,118,817

Herceptin	Q1		Q2		Q3		Q4		Total
2012	1,515,255		1,625,313		1,663,695		1,650,495		6,454,759
2011	1,391,568		1,559,975		1,642,898		1,432,771		6,027,211
2010	1,270,846		1,349,512		1,300,934		1,409,310		5,330,602
2009	1,210,268		1,133,993		1,226,435		1,278,626		4,849,323
2008	1,105,426		1,195,215		1,211,982		1,186,806		4,699,428
2007	891,761		949,556		979,602		1,015,033		3,835,952
2006	529,585		659,719		761,099		803,576		2,753,979

Lucentis	Q1		Q2		Q3		Q4		Total
2012	1,079,092		1,086,543		1,097,541		1,109,695		4,372,871
2011	887,757		943,418		1,052,809		1,075,015		3,958,999
2010	721,967		698,890		745,376		804,684		2,970,917
2009	462,103		469,736		555,296		615,212		2,102,347
2008	363,615		393,682		460,167		454,922		1,672,386
2007	224,820		219,579		299,995		322,300		1,066,695
2006	-		-		10,689		157,742		168,431

Xolair	Q1		Q2		Q3		Q4		Total
2012	310,234		314,638		347,796		340,431		1,313,100
2011	267,754		277,642		310,874		314,911		1,171,182
2010	228,859		225,878		251,055		263,389		969,180
2009	184,669		181,086		211,006		219,693		796,454
2008	137,875		169,521		177,179		183,753		668,329
2007	129,172		130,700		144,250		147,754		551,876
2006	95,241		99,354		112,608		118,002		425,204

Perjeta	Q1		Q2		Q3		Q4		Total
2012	-		-		5,080		25,000		30,079

Tysabri	Q1		Q2		Q3		Q4		Total
2012	374,430		401,743		391,623		408,711		1,576,508
2011	329,696		356,876		388,758		381,618		1,456,948
2010	293,047		287,925		293,664		316,657		1,191,292
2009	221,854		229,993		257,240		285,481		994,569
2008	129,430		163,076		200,783		233,070		726,359
2007	30,468		48,715		71,972		94,521		245,675
2006	-		-		-		7,890		7,890

Actemra	Q1		Q2		Q3		Q4		Total
2012	56,662		66,624		71,505		82,053		276,843
2011	30,433		35,370		46,709		48,671		161,183
2010	52,908		5,405		10,493		22,919		91,725
2009	19,504		17,920		30,313		39,888		107,625
2008	1,452		1,377		5,981		12,305		21,115
2007	-		-		-		1,137		1,137
2006	-		-		-		-		-

* As reported to PDL by its licensees

Totals may not sum due to rounding

Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) *

Avastin Sales	2011 - Q3		2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3		2012 - Q4
US Made & Sold	688,966		684,878		652,824		724,483		679,914		710,501
US Made & ex-US Sold	587,975		375,830		448,037		532,979		428,976		281,905
ex-US Made & Sold	304,155		409,286		401,896		316,265		442,437		670,572
Total	1,581,095		1,469,994		1,502,757		1,573,727		1,551,327		1,662,977
US Made & Sold	44%		47%		43%		46%		44%		43%
US Made & ex-US Sold	37%		26%		30%		34%		28%		17%
ex-US Made & Sold	19%		28%		27%		20%		29%		40%

Herceptin Sales	2011 - Q3		2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3		2012 - Q4
US Made & Sold	445,395		453,168		456,920		497,109		503,612		515,790
US Made & ex-US Sold	495,086		612,908		523,353		466,477		545,625		552,127
ex-US Made & Sold	702,416		366,695		534,982		661,727		614,459		582,578
Total	1,642,898		1,432,771		1,515,255		1,625,313		1,663,695		1,650,495
US Made & Sold	27%		32%		30%		31%		30%		31%
US Made & ex-US Sold	30%		43%		35%		29%		33%		33%
ex-US Made & Sold	43%		26%		35%		41%		37%		35%

Lucentis Sales	2011 - Q3		2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3		2012 - Q4
US Made & Sold	422,335		428,884		433,428		412,131		385,746		381,592
US Made & ex-US Sold	630,474		646,131		645,665		674,411		711,795		728,103
ex-US Made & Sold	-		-		-		-		-		-
Total	1,052,809		1,075,015		1,079,092		1,086,543		1,097,541		1,109,695
US Made & Sold	40%		40%		40%		38%		35%		34%
US Made & ex-US Sold	60%		60%		60%		62%		65%		66%
ex-US Made & Sold	0%		0%		0%		0%		0%		0%

Xolair Sales	2011 - Q3		2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3		2012 - Q4
US Made & Sold	184,837		188,728		185,505		193,600		211,702		210,892
US Made & ex-US Sold	-		-		-		-		-		-
ex-US Made & Sold	126,037		126,184		124,729		121,039		136,094		129,540
Total	310,874		314,911		310,234		314,638		347,796		340,431
US Made & Sold	59%		60%		60%		62%		61%		62%
US Made & ex-US Sold	0%		0%		0%		0%		0%		0%
ex-US Made & Sold	41%		40%		40%		38%		39%		38%

Perjeta Sales	2011 - Q3		2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3		2012 - Q4
US Made & Sold	-		-		-		-		5,080		24,571
US Made & ex-US Sold	-		-		-		-		-		428
ex-US Made & Sold	-		-		-		-		-		-
Total	-		-		-		-		5,080		25,000
US Made & Sold	0%		0%		0%		0%		100%		98%
US Made & ex-US Sold	0%		0%		0%		0%		0%		2%
ex-US Made & Sold	0%		0%		0%		0%		0%		0%

Total Sales	2011 - Q3		2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3		2012 - Q4
US Made & Sold	1,741,534		1,755,657		1,728,678		1,827,323		1,786,053		1,843,345
US Made & ex-US Sold	1,713,535		1,634,869		1,617,054		1,673,867		1,686,395		1,562,564
ex-US Made & Sold	1,132,608		902,165		1,061,607		1,099,031		1,192,990		1,382,690
Total	4,587,677		4,292,691		4,407,339		4,600,221		4,665,438		4,788,598
US Made & Sold	38%		41%		39%		40%		38%		38%
US Made & ex-US Sold	37%		38%		37%		36%		36%		33%
ex-US Made & Sold	25%		21%		24%		24%		26%		29%

* As reported to PDL by its licensees

Totals may not sum due to rounding

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.